Kura Oncology Overview

  • Founded
  • 2014

Founded
  • Status
  • Public

  • Employees
  • 123

Employees
  • Stock Symbol
  • KURA

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $16.23

  • (As of Friday Closing)

Kura Oncology General Information

Description

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 12730 High Bluff Drive
  • Suite 400
  • San Diego, CA 92130
  • United States
+1 (858) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kura Oncology Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.23 $16.00 $10.41 - $21.19 $1.07B 66.9M 797K -$2.00

Kura Oncology Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 740,425 395,689 1,846,703 380,451
Revenue 0 0 0 0
EBITDA (134,144) (130,700) (91,705) (67,479)
Net Income (133,331) (130,466) (89,625) (63,140)
Total Assets 471,425 534,051 647,212 241,972
Total Debt 5,892 6,875 14,977 7,752
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kura Oncology Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kura Oncology‘s full profile, request access.

Request a free trial

Kura Oncology Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics
Biotechnology
San Diego, CA
123 As of 2022
00000
00000000 00000

000000

t aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse ci
000000000000000
Cambridge, MA
00 As of 0000
00000
00000000 00000

000000

eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kura Oncology Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Infinity Pharmaceuticals Formerly PE-Backed Cambridge, MA 00 00000 00000000 00000
0000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
0000000 000000 Venture Capital-Backed Barcelona, Spain 00 0000 000000000000 0000
00000 000000000000 Formerly VC-backed Watertown, MA 000 00.000 00000000 00.000
0000000 0000000000 Corporation Framingham, MA 0 000.00 000000000 000.00
You’re viewing 5 of 30 competitors. Get the full list »

Kura Oncology Patents

Kura Oncology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3124616-A1 Therapies for squamous cell carcinomas Pending 21-Dec-2018 0000000000
AU-2019403379-A1 Therapies for squamous cell carcinomas Pending 21-Dec-2018 0000000000
US-20220071941-A1 Therapies for squamous cell carcinomas Pending 21-Dec-2018 00000000000
EP-3897638-A1 Therapies for squamous cell carcinomas Pending 21-Dec-2018 0000000000
JP-2022514654-A Treatment for squamous cell carcinoma Pending 21-Dec-2018 A61K31/223
To view Kura Oncology’s complete patent history, request access »

Kura Oncology Executive Team (16)

Name Title Board Seat Contact Info
Troy Wilson Ph.D Chief Executive Officer & Chief Financial Officer, Finance
Kathleen Ford Chief Operating Officer, Operations
Teresa Bair JD Secretary, Administration & Chief Legal Officer, Legal
Pete Spain Senior Vice President, Investor Relations and Corporate Communications
Kirsten Flowers Executive
You’re viewing 5 of 16 executive team members. Get the full list »

Kura Oncology Board Members (7)

Name Representing Role Since
Carol Schafer Kura Oncology Board Member 000 0000
Diane Parks Self Board Member 000 0000
Faheem Hasnain Self Board Member 000 0000
Mary Szela Self Board Member 000 0000
Steven Stein MD Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Kura Oncology Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kura Oncology Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Kura Oncology‘s full profile, request access.

Request a free trial

Kura Oncology Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 00000000 06-Mar-2015 0000000000 Holding Companies
To view Kura Oncology’s complete acquisitions history, request access »